Deafblind UK are delighted to share the news from Retina UK that the National Institute for Health and Care Excellence (NICE) has recommended Luxturna (voretigene neparvovec) for use in the NHS in England, making it the first available treatment for an inherited retinal dystrophy.
The Retina UK community has played a critical role in influencing NICE’s decision and their Chief Executive Tina Houlihan welcomed the news.
“The progressive and debilitating nature of this rare genetic condition places a life-long physical, emotional and financial burden on patients and their families,” she said.
“NICE’s recommendation marks a pivotal moment as, for the first time, children and adults born with this condition have a much needed treatment option.
“We very much hope this is just the start and that other therapies will soon be discovered for a wide range of inherited retinal dystrophies and made available on the NHS.”
For more information on this story please click here.